Both in Biotechnology
Pluri vs Acumen Pharmaceuticals
Over the past year PLUR returned −65.0% and ABOS returned −89.5%; their daily moves had a correlation of -0.02.
PLUR −65.0% ABOS −89.5%Growth of $1, one year, split-adjusted
| Metric | PLUR | ABOS |
|---|---|---|
| Price | $1.19 | $0.2138 |
| Market cap | $16.1M | $15.5M |
| Today | −3.26% | −1.16% |
| 1 month | +14.4% | −89.8% |
| 6 months | −64.4% | −91.3% |
| Year to date | −60.2% | −89.9% |
| 1 year | — | −89.0% |
| Revenue growth (YoY) | −15.8% | — |
| Gross margin | 58.5% | — |
| Net margin | −1755.2% | — |
| P/E (TTM) | — | — |
| Price / sales | 15.8× | — |
| Net cash | -$23.9M | $52.3M |
| Dividend yield | — | — |
| Volatility (60d) | 80.2% | 492.8% |
| Short % of float | 0.3% | 7.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).